Home LiteratureArticle Details
PMID: 7869036 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes.

The Journal of experimental medicine ·Vol. 181 ·No. 3 ·1995-03-01 ·Pages 1205-10

Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF

Abstract

TNF is synthesized as a 26-kD membrane-anchored precursor and is proteolytically processed at the cell surface to yield the mature secreted 17-kD polypeptide. The 80-kD tumor necrosis factor (TNF) receptor (TNFR80) is also proteolytically cleaved at the cell surface (shed), releasing a soluble ligand-binding receptor fragment. Since processing of TNF and TNFR80 occurs concurrently in activated T cells, we asked whether a common protease may be involved. Here, we present evidence that a recently described inhibitor of TNF processing N-(D,L-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl)L- 3-(2'naphthyl)- alanyl-L-alanine, 2-aminoethyl amide (TAPI) also blocks shedding of TNFR80, suggesting that these processes may be coordinately regulated during T cell activation. In addition, studies of murine fibroblasts transfected with human TNFR80, or a cytoplasmic deletion form of TNFR80, reveal that inhibition of TNFR80 shedding by TAPI is independent of receptor phosphorylation and does not require the receptor cytoplasmic domain.

MeSH Terms
Animals Dipeptides/pharmacology Humans Hydroxamic Acids/pharmacology Lymphocyte Activation Metalloendopeptidases/antagonists & inhibitors,physiology Mice Receptors, Tumor Necrosis Factor/antagonists & inhibitors,metabolism T-Lymphocytes/metabolism Transfection Tumor Necrosis Factor-alpha/antagonists & inhibitors,metabolism
Chemicals
Dipeptides Hydroxamic Acids N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Metalloendopeptidases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Crowe P D
Division of Biomedical Sciences, University of California, Riverside 92521.
Walter B N
Mohler K M
Otten-Evans C
Black R A
Ware C F
References (26)
26 references, click to expand
  1. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact.
    Cell. 1990 Oct 19;63(2):251-8 PMID: 2208285
  2. Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor.
    Proc Natl Acad Sci U S A. 1990 Aug;87(16):6151-5 PMID: 2166946
  3. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
    Proc Natl Acad Sci U S A. 1990 Nov;87(22):8781-4 PMID: 2174164
  4. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.
    Cancer Res. 1991 Oct 15;51(20):5602-7 PMID: 1655258
  5. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells.
    J Immunol. 1991 Dec 15;147(12):4229-38 PMID: 1661312
  6. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.
    J Exp Med. 1992 Feb 1;175(2):323-9 PMID: 1310100
  7. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
    Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845-9 PMID: 1317575
  8. Plasma tumor necrosis factor soluble receptors in chronic renal failure.
    Kidney Int. 1992 Sep;42(3):663-7 PMID: 1328755
  9. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.
    Arthritis Rheum. 1992 Oct;35(10):1160-9 PMID: 1329774
  10. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.
    Arthritis Rheum. 1992 Oct;35(10):1170-8 PMID: 1329775
  11. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain.
    Eur J Cell Biol. 1992 Aug;58(2):307-12 PMID: 1330568
  12. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection.
    AIDS. 1993 Jan;7(1):33-6 PMID: 8382926
  13. Multiple cytokine secretion by IL-7-stimulated human T cells.
    Cytokine. 1992 Nov;4(6):461-9 PMID: 1292630
  14. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.
    Arthritis Rheum. 1993 Aug;36(8):1111-20 PMID: 8393677
  15. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation.
    J Immunol. 1993 Dec 15;151(12):6882-90 PMID: 8258697
  16. Tumor necrosis factor, other cytokines and disease.
    Annu Rev Cell Biol. 1993;9:317-43 PMID: 8280464
  17. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.
    Nature. 1994 Jul 21;370(6486):218-20 PMID: 8028669
  18. Processing of tumour necrosis factor-alpha precursor by metalloproteinases.
    Nature. 1994 Aug 18;370(6490):555-7 PMID: 8052310
  19. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.
    Nature. 1994 Aug 18;370(6490):558-61 PMID: 8052311
  20. Transient modulation and internalization of T4 antigen induced by phorbol esters.
    J Immunol. 1986 Aug 15;137(4):1194-201 PMID: 3090141
  21. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.
    Cell. 1988 Apr 8;53(1):45-53 PMID: 3349526
  22. Isolation and characterization of a tumor necrosis factor binding protein from urine.
    Eur J Haematol. 1989 Mar;42(3):270-5 PMID: 2924890
  23. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.
    J Immunol. 1990 Apr 1;144(7):2582-91 PMID: 1969453
  24. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.
    Science. 1990 May 25;248(4958):1019-23 PMID: 2160731
  25. Shedding of tumor necrosis factor receptors by activated human neutrophils.
    J Exp Med. 1990 Aug 1;172(2):599-607 PMID: 2165128
  26. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
    EMBO J. 1990 Oct;9(10):3269-78 PMID: 1698610
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1995-03-01
Pages
1205-10
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2191902
Subset
IM
Grants
NIAID NIH HHS · R01 AI33068 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com